Evaluation of efficacy of topical bromfenac (0.1%) as an adjunctive therapy for patients with retinal vein occlusion

Evaluation of efficacy of topical bromfenac (0.1%) as an adjunctive therapy for patients with retinal vein occlusion - Efficacy of topical bromfenac for retinal vein occlusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013410

Enrollment

Registered

2014-03-14

Start date

2014-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

topical bromfenac as an adjunctive therapy to intravitreal injection of ranibizumab topical artificail tears as the sham of blomfenac to intravitreal injection of ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science Hospital with retinal vein occlusion that are examined by angiography or checked retinal thickness.

Exclusion criteria

Exclusion criteria: severe renal disease unstable angina malignant arrhythmia history of brain infarction history of cerebral hemorrhage severe hypertension

Design outcomes

Primary

Measure	Time frame
total number of injections of ranibizumab during 12 months' follow-up	—

Secondary

Measure	Time frame
Variation on a central retinal thickness	—

Countries

Japan

Contacts

Public ContactYoshitsugu Saishin

Shiga University of Medical Science Department of Ophthalmology

saishin@belle.shiga-med.ac.jp077-548-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026